IP Library Granted Patent US 12,006,549
Granted Patent B2
US 12,006,549 · App. 17/269,092 · Granted Jun 11, 2024

Methods utilizing leukocyte RNA expression in prognosis evaluation of medical interventions for epilepsy

Inventors: Martin E. Weinand (Tucson, AZ); Ryan Sprissler (Tucson, AZ); Michael F. Hammer (Tucson, AZ)
Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
C12Q1/6883C12Q1/686A61N7/00C12Q2600/158G01N2800/2857G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,006,549
App. No.
17/269,092
Granted
Jun 11, 2024
Kind
B2
Abstract

Methods involving analysis of pretreatment leukocyte expression profiles for prognostic assessment of seizure outcome following a treatment or medical procedure, such as stereotactic laser amygdalohippocampotomy (SLAH). In one aspect, RNA sequencing (RNA-Seq) on whole blood leukocyte samples is taken from a patient with intractable epilepsy prior to SLAH. Differential expression (DE) analysis revealed 24 significantly dysregulated genes (≥2.0-fold change, p-value <0.05, and False Discovery Rate, FDR <0.05) useful in prognostic assessment.

Claims (9)

1. A method of treating a subject with intractable epilepsy, comprising the steps of:

a) obtaining RNA from leukocytes from the subject;

b) based on the RNA present in the leukocytes, determining an expression level of 24 genes consisting of: FAM155A, ABCA4, ZFP57, IFI27, C5orf17, PLP1, PVRL2, FAM118A, GFAP, CDYL, CPEB4, FADS2, RSAD2, BIN3, BRSK1, AKAP7, IL22RA1, BGN, MMP8, PF4VI, MDGA1, ALOX15B, HBG1, and B4GALNT3;

c) comparing the determined expression level with a control expression level for each gene;

d) detecting upregulation of FAM155A, ABCA4, ZFP57, IFI27, C5orf17, PLP1, PVRL2, FAM118A, GFAP, CDYL, CPEB4, FADS2, RSAD2, BIN3, BRSK1, and AKAP7, and detecting downregulation of IL22RA1, BGN, MMP8, PF4VI, MDGA1, ALOX15B, HBG1, and B4GALNT3 relative to the control expression level for each gene; and

e) treating the subject with ablation treatment.

2. The method of claim 1 , wherein step c) comprises one or more of quantitative real time polymerase chain reaction (PCR) and digital droplet PCR.

3. The method of claim 1 , wherein said ablation treatment comprises stereotactic laser amygdalohippocampotomy (SLAH) ablation of the amygdala and the hippocampus, from the amygdala anteriorly to the hippocampus at least at a level of the tectum posteriorly.

4. The method of claim 1 , wherein said ablation treatment comprises an MRI-guided focused ultrasound or a focused ultrasound-based intervention.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2023
From: WEINAND, MARTIN E.; SPRISSLER, RYAN; HAMMER, MICHAEL F.
To: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
Reel/Frame 063582/0370 →
CONFIRMATORY LICENSE Recorded Jan 4, 2023
From: UNIVERSITY OF ARIZONA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 062277/0889 →
Continuity (2)
Provisional Application 62741719 · Oct 5, 2018
Related Publication 20210246509A1 · Aug 12, 2021